Feature

Of ‘miracles’ and money: Why hemophilia drugs are so expensive


 

Sitting at a picnic bench at a park, Jessica Morris pages through Landon’s insurance documents. Over the past year, his care cost over $120,000. She wonders sometimes what would happen if they lost their coverage.

“How much would you be willing to pay to have your child lead a normal life?” she said. “I don’t think that there’s anything we wouldn’t pay or sacrifice for him.”

It’s a problem she prays they’ll never have to face.

Kaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente. KHN’s coverage of prescription drug development, costs, and pricing is supported by the Laura and John Arnold Foundation.

Pages

Recommended Reading

Watchful waiting a suitable option for pediatric acute ITP
MDedge Pediatrics
FDA advisory committee supports L-glutamine for SCD
MDedge Pediatrics
FDA approves Rebinyn for hemophilia B treatment
MDedge Pediatrics
Prophylactic emicizumab cut bleeds by 87% in hemophilia A with inhibitors
MDedge Pediatrics
Monthly fitusiran showed promise in small phase I hemophilia trial
MDedge Pediatrics
Vaccination does not eliminate risk for meningococcal disease in eculizumab recipients
MDedge Pediatrics
Allele-matching in cord blood transplant yields better survival
MDedge Pediatrics
HAVEN 2: Emicizumab represents new standard of care for hemophilia A with inhibitors
MDedge Pediatrics
FDA grants breakthrough therapy designation for severe aplastic anemia drug
MDedge Pediatrics
States strive to curb costs for a crucial – but exorbitant – hemophilia treatment
MDedge Pediatrics